biomarker‑targeted longevity therapy
Experts Warn: Longevity Science Masks Emerging Risks
Ninety percent of anti-aging deals remain in pre-clinical stages, underscoring a hidden risk landscape. Longevity science often masks regulatory lag, biomarker over-dependence, and market volatility, leaving investors and patients exposed to unforeseen setbacks. Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult